16 results about "Integrin Receptor" patented technology

The application provides a multifunctional nano particle for targeting abdominal aortic aneurysm and a preparation method and application thereof, and belongs to the field of nanobiomedicine, wherein polyphenol oxidation self-polymer nanoparticles are used as carriers, doxycycline is loaded, and a targeting ligand cRGD is modified on the surface of the nano carrier; the neovasculature in the media and adventitia of AAA sites helps accumulation of the nanoparticles in the abdominal aortic aneurysm, and the integrin αν3 beta receptor highly expressed on the surface of the diseased cell membrane can recognize the cRGD with high affinity, and then mediate the targeted endocytosis of the nanoparticles; after intravenous injection, the nanoparticles can be effectively enriched in the lesion site and achieve long-term retention, and can release DC in response to the high ROS level in the tumor microenvironment; the drug is rapidly released to take effect, and the non-specific toxic side effects are reduced; the free radical scavenging capacity of the nanoparticles can be synergized with the DC activity to treat AAA through multiple mechanisms such as anti-inflammatory, antioxidant, macrophage repolarization promotion, anti-apoptosis and calcification inhibition, and MMPs inhibition.

The invention provides a bacterial outer membrane vesicle drug carrier with a targeting effect and preparation, and relates to the technical field of biological medicines.The bacterial outer membrane vesicle protein ClyA derived from an escherichia coli W3110 strain is combined with iRGD protein capable of being combined with an integrin receptor alpha v beta 3, a ClyA-iRGD-pGEX-6P-1 recombinant plasmid for expressing ClyA-iRGD fusion protein is constructed, and the ClyA-iRGD-pGEX-6P-1 recombinant plasmid is used for preparing the bacterial outer membrane vesicle drug carrier with the targeting effect. By endogenous expression of the plasmid in W3110 escherichia coli, the C-iRGD-OMVs which has a tumor targeting effect and shows ClyA-iRGD fusion protein on the surface is prepared. The C-iRGD-OMVs shows efficient targeting binding capacity to MCF-7 breast cancer cells, overcomes the defect that iRGD single peptide is prone to aggregation and crystallization, has the potential of loading drugs, lays a foundation for the C-iRGD-OMVs serving as a targeting carrier for delivering breast cancer treatment drugs, and is expected to be further developed into a targeting treatment preparation for breast cancer.

This invention relates to the field of biomedical polymer materials and surface modification engineering, specifically to a posterior scleral reinforcement material and its preparation method. It comprises a polymer matrix and a bioactive modified layer formed by the oxidative crosslinking of a heterobifunctional polymer coupling compound. This copolymer structure includes anchoring groups, hydrophilic linkers, and bioactive groups. Its core principle is to utilize the flexible extension of the hydrophilic linkers to reduce steric hindrance, fully exposing the bioactive groups to the material surface, thereby achieving efficient recognition and binding to integrin receptors. This invention effectively solves the problems of bioinertness of the synthesized polymer matrix and lack of cell recognition sites, achieving a cell proliferation rate more than twice that of the unmodified matrix, demonstrating the material's excellent bioactivity and cell compatibility.

The application discloses a lung cancer dual-targeting photodynamic synergistic ferroptosis diagnosis and treatment integrated probe and a preparation method and application thereof. The probe is dual-targeted on integrin receptors and high-order sulfonic acidization characteristics which are highly expressed in tumor cells, realizes efficient enrichment and long-term retention of the probe in a tumor site. Meanwhile, by integrating photodynamic therapy and ferroptosis therapy, the degree of lipid peroxidation of cells is promoted, the progress of tumors is effectively inhibited, and diagnosis and treatment integration of the tumors is realized.

The application belongs to the technical field of biological medicine, and discloses application of a simulation polypeptide containing a fibrinogen RGD module in preparation of a medicine for preventing and / or treating Parkinson's disease. The sequence of the simulation polypeptide containing the fibrinogen RGD module is Gly-Arg-Gly-Asp-Ser-Pro-Lys-Asn-Pro-Ser-Cys. The applicant of the application finds that FG abnormally accumulates in the substantia nigra compacta of a PD mouse, and the FG excessively accumulated in the brain may promote abnormal aggregation of alpha-syn of dopaminergic neurons through mediation of an alpha v beta 3 integrin receptor. The simulation polypeptide provided by the application can effectively inhibit abnormal aggregation of alpha-syn of dopaminergic neurons caused by the abnormally accumulated FG in the brain and death of the dopaminergic neurons, improve the motor ability of the PD mouse modeled by MPTP, and provide a new target and thought for PD treatment.

The invention discloses metal-based nanoparticles loaded with traditional Chinese medicine as well as a preparation method and application of the metal-based nanoparticles, and relates to the technical field of nano medical materials. The nano-particle is prepared by taking nickel iron zinc aluminum hydroxide as a multi-metal-based core carrier, carrying out PEG modification and cRGD peptide targeted coupling, and loading a traditional Chinese medicine active ingredient curcumin. The preparation is realized through a multi-step chemical coupling and loading process, and the multi-metal carrier can realize responsive structural disintegration and accurate controlled release of curcumin in a tumor weak acid environment. The nanoparticles have active targeting, multi-metal synergistic killing and immune regulation functions, can specifically recognize a triple negative breast cancer cell surface integrin alpha v beta 3 receptor, inhibit tumor cell proliferation, induce apoptosis, regulate BCR, IL-17 and other immune related signal channels, promote immune cell infiltration and remodel a tumor immune microenvironment. The metal-based nano-particles loaded with the traditional Chinese medicine are simple in preparation process, high in production efficiency and suitable for precise treatment of triple negative breast cancer.

The invention discloses a hypoxia activating peptide-photosensitizer-drug conjugate and a preparation method and application thereof in the technical field of medicine, the conjugate takes indocyanine with a high molar extinction coefficient as a photosensitive core, distorted conjugate units are introduced to two sides of indole, the characteristic of'limited movement in molecules' is given to the conjugate, and radiation and non-radiation energy dissipation are balanced. Meanwhile, an azo bond sensitive to hypoxia is reasonably introduced between a light treatment module and a chemotherapy module to serve as a responsive linker, and is further coupled with two-molecule integrin targeting peptide cRGD, so that the azo bond is self-assembled into nanospheres in an aqueous solution, and a triple targeting mechanism, namely multivalent integrin receptor targeting, aggregation and tumor microenvironment hypoxia selective activation, is realized. In an in-situ osteosarcoma mouse model, the conjugate realizes real-time near-infrared two-region imaging, shows potent tumor inhibition, effectively inhibits lung metastasis, and does not detect obvious systemic toxicity.

The invention provides a near-infrared NIR-II region fluorescence ratio probe based on tumor-associated neutrophil and application of the near-infrared NIR-II region fluorescence ratio probe. The nanoprobe is a rare earth doped down-conversion nanocrystal with a core-shell structure, the surface of the rare earth doped down-conversion nanocrystal is modified with a response unit and a targeting unit, and the response unit can release a fluorescence signal through enzymatic cleavage of neutrophil elastase; and the targeting unit is used for targeting a tumor microenvironment integrin receptor. The nanoprobe has high specificity and sensitivity, high anti-interference capability and self-calibration capability, can realize NIR-IIb region ratio imaging, provides a key basis for early curative effect judgment, achieves accurate individual stratification, fills the technical blank of cancer immunotherapy curative effect monitoring, and promotes the development of a tumor immune microenvironment molecular imaging technology.

This invention relates to a self-assembling polypeptide for regulating the permeability of retinal pigment epithelium (RPE), its preparation method, and its applications. The self-assembling polypeptide comprises an integrin receptor-targeting peptide, a self-assembling polypeptide, and a hydrophobic molecule sequentially linked. The self-assembling polypeptide designed in this invention can self-assemble into nanoparticles and specifically target RPE cells. After interacting with receptors on the cell membrane, the nanoparticles transform into nanofibers, achieving rapid targeted enrichment of RPE tissue. Furthermore, by regulating the permeability of RPE tissue, it can enhance the transcellular drug transport capacity, providing a new clinical application strategy for the treatment of macular neovascularization, especially polypoid choroidal vascular lesions.

The invention relates to the technical field of cell separation and purification and cell biological detection, in particular to a method for separating and purifying fetal NRBC from peripheral blood of a pregnant woman. The invention provides a method for separating and purifying fetal NRBC from peripheral blood of a pregnant woman, which is characterized in that a LukSF and LukAB bi-component perforation toxin is designed and utilized to specifically recognize and split a CXCR1 / 2 chemotactic factor receptor and a CD11b / CD18 integrin receptor on the surface of maternal leukocyte, and the fetal NRBC is completely reserved due to lack of corresponding receptors, so that the fetal NRBC can be separated and purified. Therefore, leukocyte pollution in nucleated red blood cells of a peripheral blood fetus of a pregnant woman is efficiently removed. According to the method, the purity of the extracted fetal NRBC can be improved, the false positive of gene detection is greatly reduced, the activity and integrity of the NRBC are reserved, and the accurate diagnosis requirements of chromosome karyotype analysis, monogenic disease detection and the like are met; the method is simple to operate and low in cost, can be directly adapted to existing clinical laboratory equipment, and has large-scale popularization value.

The invention discloses a pathological blood-brain barrier targeting nano preparation for treating Alzheimer's disease and a preparation method thereof, and belongs to the technical field of biological medicines.The nano preparation takes nanoparticles formed by assembling amphiphilic block copolymers as a carrier, RAP peptide and RGD peptide are co-modified on the surface of the carrier, and the nano preparation is prepared. The RAP peptide can specifically recognize and combine with an RAGE receptor highly expressed by vascular endothelial cells in a pathological state, so that precise targeting is realized, and the RAP peptide also has the activity of blocking an RAGE-AB pathological pathway; the RGD peptide serves as an integrin binding motif, the endocytosis efficiency of the nanoparticle can be remarkably enhanced through the interaction with a cell surface integrin receptor, transfer of the nanoparticle to lysosome after endocytosis is promoted, and through the synergistic effect of the two ligands, the nanoparticle can be efficiently targeted to lesion cerebrovascular endothelium expressing RAGE and can also be efficiently targeted to the lesion cerebrovascular endothelium expressing RAGE. The RAGE protein can be effectively internalized and guided to the lysosome, so that the degradation of the RAGE protein is enhanced by virtue of a lysosome way while the targeted drug delivery is realized, and the active intervention on a key pathological pathway is realized.

The invention discloses an RGD targeted diagnosis and treatment integrated boron medicine as well as preparation and application thereof. The core innovation lies in that a photoacoustic imaging molecule taking boron-10 isotope as a core is designed, and the molecule has double functions: the molecule is used as a photoacoustic imaging unit to realize visual positioning of tumors, and is also used as a boron-10 unit required by boron neutron capture therapy (BNCT) to realize diagnosis and treatment integration on the molecular level. The core molecule is modified through carboxylation derivation, so that the core molecule can be efficiently connected with RGD tumor targeting peptide through an amido bond, and a targeting diagnosis and treatment conjugate is constructed. The conjugate can specifically recognize an alpha v beta 3 integrin receptor on the surface of a tumor vascular endothelial cell, and the tumor targeting property is remarkably improved. The invention not only provides an innovative drug design platform, but also solves the problem of separation of diagnosis and treatment in traditional BNCT through molecular structure optimization, and provides a reliable technical basis for accurate imaging-guided boron neutron capture therapy.

The invention relates to the technical field of tumor treatment, and discloses a treatment type ultrasonic microbubble for tumor ultrasonic treatment and a preparation method thereof.The treatment type ultrasonic microbubble is formed by combining an ultrasonic contrast agent microbubble and a novel treatment factor, a shell of the treatment type ultrasonic microbubble for tumor ultrasonic treatment is made of PCL-PEG-RGD copolymer, the RGD peptide fragment can be specifically combined with a tumor cell surface integrin receptor, so that precise targeting is realized, and the aggregation concentration of a therapeutic factor at a tumor part is improved to enhance the curative effect; the novel therapeutic factor ETV contains a tumor specific activation fragment and is only activated by enzymolysis in a tumor microenvironment, so that damage to normal tissues can be avoided, toxic and side effects can be reduced, and treatment safety can be guaranteed; the microbubbles and the ETV are covalently bound through an EDC-NHS mixed activator, the binding is stable, the falling of therapeutic factors can be prevented, the dosage delivered to a tumor site is ensured, the preparation process is simple and convenient, the reaction conditions are easy to control, the used materials are good in biocompatibility, the in-vivo use safety is further ensured, and the tumor ultrasonic treatment effect and safety are comprehensively improved.

The invention discloses a lung cancer dual-targeting photodynamic synergistic ferroptosis diagnosis and treatment integrated probe as well as a preparation method and application thereof, the probe takes a high-expression integrin receptor of a tumor cell and a high-order sulfonation characteristic as dual targeting, and the effects of efficient enrichment and long-acting retention of the probe at a tumor part are realized. Meanwhile, by integrating photodynamic treatment and ferroptosis treatment, the lipid peroxidation degree of cells is promoted, the tumor progress is effectively inhibited, and tumor diagnosis and treatment integration is achieved.

The application discloses a pathological blood-brain barrier targeting nano-preparation for treating Alzheimer's disease and a preparation method thereof, and belongs to the technical field of biological medicine. The nano-preparation takes nanoparticles assembled by an amphiphilic block copolymer as a carrier, and is co-modified with RAP peptides and RGD peptides on the surface. The RAP peptides can specifically recognize and bind to the RAGE receptor which is highly expressed by vascular endothelial cells in a pathological state, so that precise targeting is realized, and the RAP peptides also have the activity of blocking the RAGE-AB pathological pathway. The RGD peptides serve as an integrin binding motif, can significantly enhance the endocytosis efficiency of the nanoparticles through the interaction with the cell surface integrin receptor, and promote the transportation of the nanoparticles to lysosomes after endocytosis. Through the synergistic effect of the two ligands, the nanoparticles can not only be efficiently targeted to the diseased brain vascular endothelium expressing RAGE, but also be effectively internalized and guided to lysosomes, so that the targeted drug delivery is realized, the degradation of the RAGE protein is enhanced by means of the lysosome pathway, and the active intervention on the key pathological pathway is realized.